α-Bisabolol suppresses the inflammatory response and ECM catabolism in advanced glycation end products-treated chondrocytes and attenuates murine osteoarthritis

Int Immunopharmacol. 2020 Jul:84:106530. doi: 10.1016/j.intimp.2020.106530. Epub 2020 Apr 22.

Abstract

As a chronic musculoskeletal degeneration disease, osteoarthritis (OA) clinically manifests as joint pain, stiffness and a limited range of movement. OA has affected the life quality of at least one-tenth of the population but lacks satisfactory treatments. α-Bisabolol (BISA) is a small oily sesquiterpene alcohol widely found in essential oils of chamomile (Matricaria recutita), salvia and wood of Candeia and has multiple biological properties, particularly an anti-inflammatory effect. The purpose of this study is to assess the anti-inflammatory and chondroprotective effect of BISA in OA progression and explore its underlying mechanism. We isolated human chondrocytes and treated them with advanced glycation end products (AGEs) to imitate OA progression in vitro. BISA pretreatment suppressed the AGE-induced inflammatory reaction and extracellular matrix (ECM) degeneration by blocking nuclear factor kappa B (NF-κB), p38 and c-Jun N-terminal kinase (JNK) signaling. Moreover, a mouse destabilization of the medial meniscus (DMM) model was established by surgery to investigate BISA protection in vivo. BISA administration attenuated DMM-induced radiological and histopathological changes relative to the DMM group and resulted in lower OARSI scores. Taken together, the results of our study indicate the potential of BISA in OA therapy.

Keywords: Advanced glycation end products; Osteoarthritis; α-Bisabolol.

MeSH terms

  • Aged
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Chondrocytes / drug effects
  • Extracellular Matrix / drug effects
  • Female
  • Glycation End Products, Advanced / pharmacology
  • Humans
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Knee Joint / drug effects
  • Knee Joint / pathology
  • Male
  • Mice, Inbred C57BL
  • Middle Aged
  • Monocyclic Sesquiterpenes / pharmacology
  • Monocyclic Sesquiterpenes / therapeutic use*
  • NF-kappa B / metabolism
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / metabolism
  • Osteoarthritis / pathology
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Anti-Inflammatory Agents
  • Glycation End Products, Advanced
  • Monocyclic Sesquiterpenes
  • NF-kappa B
  • bisabolol
  • JNK Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases